Literature DB >> 11766734

Inhibitory effect of ginsenoside-Rb2 on invasiveness of uterine endometrial cancer cells to the basement membrane.

J Fujimoto1, H Sakaguchi, I Aoki, H Toyoki, S Khatun, T Tamaya.   

Abstract

Ginsenoside-Rb2 derived from ginseng inhibited invasiveness to the basement membrane of endometrial cancer cell lines Ishikawa. HHUA and HEC-1-A cells. These cells dominantly expressed matrix metalloproteinase (MMP)-2 (gelatinase A) among MMPs by zymography. Ginsenoside-Rb2 suppressed the expression and activity of MMP-2, but did not alter the expression of tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in the cells. Therefore, ginsenoside-Rb2 might inhibit invasiveness to the basement membrane via MMP-2 suppression in some endometrial cancers, and can be used as a medicine for inhibition of secondary spreading of uterine endometrial cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11766734

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  13 in total

1.  Ginsenoside Rb2 enhances the anti-inflammatory effect of ω-3 fatty acid in LPS-stimulated RAW264.7 macrophages by upregulating GPR120 expression.

Authors:  Qi Huang; Ting Wang; He-Yao Wang
Journal:  Acta Pharmacol Sin       Date:  2016-12-26       Impact factor: 6.150

2.  Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.

Authors:  Kiyono Osanai; Yoichi Kobayashi; Masahiro Otsu; Tomoko Izawa; Keiji Sakai; Mitsutoshi Iwashita
Journal:  Hum Cell       Date:  2017-04-05       Impact factor: 4.174

Review 3.  Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine.

Authors:  Lee Jia; Yuqing Zhao; Xing-Jie Liang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

4.  Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells.

Authors:  Chun-Jie Gu; Jiao Cheng; Bing Zhang; Shao-Liang Yang; Feng Xie; Jian-Song Sun; Li-Qing Huang; Jin-Jin Yu; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

5.  Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.

Authors:  Subhasree Ashok Nag; Jiang-Jiang Qin; Wei Wang; Ming-Hai Wang; Hui Wang; Ruiwen Zhang
Journal:  Front Pharmacol       Date:  2012-02-28       Impact factor: 5.810

6.  Isolation and characterization of saponin-producing fungal endophytes from Aralia elata in Northeast China.

Authors:  Hao Wu; Hongyan Yang; Xiangling You; Yuhua Li
Journal:  Int J Mol Sci       Date:  2012-11-30       Impact factor: 5.923

7.  Ginseng and Its Active Components Ginsenosides Inhibit Adipogenesis in 3T3-L1 Cells by Regulating MMP-2 and MMP-9.

Authors:  Jaeho Oh; Hyunghee Lee; Dongmin Park; Jiwon Ahn; Soon Shik Shin; Michung Yoon
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-14       Impact factor: 2.629

8.  Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides.

Authors:  Patrick Ying Kit Yue; Nai Ki Mak; Yuen Kit Cheng; Kar Wah Leung; Tzi Bun Ng; David Tai Ping Fan; Hin Wing Yeung; Ricky Ngok Shun Wong
Journal:  Chin Med       Date:  2007-05-15       Impact factor: 5.455

9.  A key role of microRNA-29b for the suppression of colon cancer cell migration by American ginseng.

Authors:  Deepak Poudyal; Xiangli Cui; Phuong Mai Le; Anne B Hofseth; Anthony Windust; Mitzi Nagarkatti; Prakash S Nagarkatti; Aaron J Schetter; Curtis C Harris; Lorne J Hofseth
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

Review 10.  Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites.

Authors:  Xiao-Jia Chen; Xiao-Jing Zhang; Yan-Mei Shui; Jian-Bo Wan; Jian-Li Gao
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.